Cytotoxicity of macrolide antibiotics in a cultured human liver cell line

被引:26
作者
Viluksela, M [1 ]
Vainio, PJ [1 ]
Tuominen, RK [1 ]
机构
[1] UNIV HELSINKI, DEPT PHARMACOL & TOXICOL, INST BIOMED, FIN-00014 HELSINKI, FINLAND
关键词
D O I
10.1093/jac/38.3.465
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Cytotoxicity of erythromycin base, erythromycin estolate, erythromycin-11,12-cyclic carbonate, roxithromycin, clarithromycin and azithromycin was compared in cultured human non-malignant Chang liver cells using reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and cellular protein concentration as end points of toxicity. Erythromycin estolate was the most toxic macrolide in all tests differing clearly from all the other macrolides studied. Erythromycin-11,12-cyclic carbonate was also more toxic than the other macrolides. Roxithromycin and clarithromycin were the next toxic derivatives, while erythromycin base and azithromycin were least toxic. Thus, cytotoxicity of the new semisynthetic macrolides, roxithromycin, clarithromycin and azithromycin, is not substantially different from that of erythromycin base. In view of the low level of hepatotoxicity of macrolides hitherto reported in humans, the results do not suggest any substantial risk for hepatic disorders related to the use of azithromycin, clarithromycin and roxithromycin.
引用
收藏
页码:465 / 473
页数:9
相关论文
共 25 条
[1]   PHARMACOLOGY AND TOXICOLOGY OF PROPIONYL ERYTHROMYCIN ESTER LAURYL SULFATE [J].
ANDERSON, RC ;
LEE, CC ;
WORTH, HM ;
HARRIS, PN .
JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION, 1959, 48 (11) :623-628
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]  
CHANG RSM, 1954, P SOC EXP BIOL MED, V87, P440
[4]   DUAL EFFECTS OF MACROLIDE ANTIBIOTICS ON RAT-LIVER CYTOCHROME-P-450 - INDUCTION AND FORMATION OF METABOLITE-COMPLEXES - A STRUCTURE-ACTIVITY RELATIONSHIP [J].
DELAFORGE, M ;
JAOUEN, M ;
MANSUY, D .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (15) :2309-2318
[5]   HEPATOTOXIC AND CELLULAR UPTAKE INTERACTIONS AMONG SURFACE-ACTIVE COMPONENTS OF ERYTHROMYCIN PREPARATIONS [J].
DUJOVNE, CA .
BIOCHEMICAL PHARMACOLOGY, 1978, 27 (15) :1925-1930
[6]  
DUJOVNE CA, 1970, ARCH INT PHARMACOD T, V186, P84
[7]   ERYTHROMYCIN ESTOLATE VS ERYTHROMYCIN BASE, SURFACE EXCESS PROPERTIES AND SURFACE-SCANNING CHANGES IN ISOLATED LIVER-CELL SYSTEMS [J].
DUJOVNE, CA ;
SALHAB, AS .
PHARMACOLOGY, 1980, 20 (06) :285-291
[8]   LIVER-CELL CULTURE TOXICITY AND SURFACTANT POTENCY OF ERYTHROMYCIN DERIVATIVES [J].
DUJOVNE, CA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1975, 32 (01) :11-20
[9]  
FRANKLIN MR, 1991, METHOD ENZYMOL, V206, P559
[10]  
GINSBURG CM, 1980, ANTIMICROBIAL THERAP, P84